Sanofi (SNYNF) Operating Income (2009 - 2026)
Sanofi's (SNYNF) quarterly Operating Income came in at $2.5 billion in Q1 2026, up 3.31% year-on-year from $2.4 billion in Q1 2025, and up 144.47% quarter-over-quarter from -$5.6 billion in Q4 2025.
Sanofi (SNYNF) Operating Income (2009 - 2026) Analysis & Trends
Sanofi has disclosed Operating Income across 18 years of filings, most recently posting $2.5 billion for Q1 2026.
- Operating Income for Q1 2026 came in at $2.5 billion, up 3.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.2 billion (down 15.84% YoY), and the FY2025 annual result was $7.4 billion, down 4.71% from the prior year.
- Operating Income came in at $2.5 billion for Q1 2026 at Sanofi, up from -$5.6 billion in the prior quarter.
- In the past five years, Operating Income ranged from a high of $8.6 billion in Q3 2025 to a low of -$5.6 billion in Q4 2025.
- The 5-year median for Operating Income is $2.5 billion (2026), against an average of $2.6 billion.
- Across the five-year window, Operating Income surged 148.25% in 2022 and slumped 1011.95% in 2025, its largest moves.
- Sanofi's Operating Income stood at $4.2 billion in 2022, then jumped by 78.89% to $7.5 billion in 2023, then slumped by 91.82% to $612.3 million in 2024, then plunged by 1011.95% to -$5.6 billion in 2025, then surged by 144.47% to $2.5 billion in 2026.
- The last three Operating Income figures came in at $2.5 billion (Q1 2026), -$5.6 billion (Q4 2025), and $8.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | 3.09 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 9.50 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 6.36 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 3.99 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | -7.73 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 2.67 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 2.59 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | -6.71 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | -182.00 Mn |
| 10 | Sanofi | - | - | 9.49 Bn | 2.48 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.48 Bn |
| Dec 31, 2025 | -5.58 Bn |
| Sep 30, 2025 | 8.63 Bn |
| Jun 30, 2025 | 1.67 Bn |
| Mar 31, 2025 | 2.40 Bn |
| Dec 31, 2024 | 612.31 Mn |
| Sep 30, 2024 | 3.89 Bn |
| Jun 30, 2024 | 1.65 Bn |
| Mar 31, 2024 | 1.34 Bn |
| Dec 31, 2023 | 7.49 Bn |
| Sep 30, 2023 | 3.50 Bn |
| Jun 30, 2023 | 2.02 Bn |
| Mar 31, 2023 | 2.64 Bn |
| Dec 31, 2022 | 4.19 Bn |
| Sep 30, 2022 | 2.75 Bn |
| Jun 30, 2022 | 1.53 Bn |
| Mar 31, 2022 | 2.69 Bn |
| Dec 31, 2021 | 1.69 Bn |
| Sep 30, 2021 | 3.58 Bn |
| Jun 30, 2021 | 1.85 Bn |